4//SEC Filing
TOWERS CHRISTOPHER 4
Accession 0001493152-23-036582
CIK 0001725430other
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 6:45 PM ET
Size
11.0 KB
Accession
0001493152-23-036582
Insider Transaction Report
Form 4
TOWERS CHRISTOPHER
Director
Transactions
- Purchase
Common Stock
2023-10-04+9,090→ 9,880 total - Purchase
Common Stock Warrants (Series F)
2023-10-04+9,090→ 9,090 totalExp: 2025-04-04→ Common Stock (9,090 underlying) - Purchase
Common Stock Warrants (Series E)
2023-10-04+9,090→ 9,090 totalExp: 2029-04-04→ Common Stock (9,090 underlying)
Footnotes (4)
- [F1]The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
- [F2]The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
- [F3]The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
- [F4]On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.
Documents
Issuer
INTELLIGENT BIO SOLUTIONS INC.
CIK 0001725430
Entity typeother
Related Parties
1- filerCIK 0001775875
Filing Metadata
- Form type
- 4
- Filed
- Oct 5, 8:00 PM ET
- Accepted
- Oct 6, 6:45 PM ET
- Size
- 11.0 KB